My management fails to fully capture scenario means that for whatever reason they fail to properly advance the potential of Leronlimab and have to sell at a "fire sale" price of 2-3 billion. CYDY has such limited management infrastructure that I don't think they can take the drug very far on their own. Will they accept a BO? Will they find a suitable partner? How much will that partner cost? These are unknown questions and the right answers will be more challenging than most here expect. That being said, I believe 2-3 billion for shareholders at some point is the low end of my expectations for the value they will ultimately realize for shareholders. I hope that makes sense.